TROG 04.01 - Cavilon Breast - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Clinical Trial Registration

Registration Link

Geoff Zipper - aka Swamp - on the Kokoda Trail

26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

TROG 2024 Annual Research Report highlights a year of achievements

TROG 04.01 – Cavilon Breast

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

TROG 2024 Annual Research Report highlights a year of achievements